Mast Cell Leukemia: An Update with a Practical Review.

Autor: Zanelli M; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy., Quintini M; Hematology, Centro di Ricerca Emato-Oncologica-C.R.E.O., University of Perugia, 06129 Perugia, Italy., Magnasco S; Pathology Unit, Ospedale SS Annunziata di Taranto, 74121 Taranto, Italy., Aprile L; Hematology Unit, Presidio Ospedaliero S.G. Moscati di Taranto, 74010 Taranto, Italy., Palicelli A; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy., Zizzo M; Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy., Sanguedolce F; Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy., Ricci S; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy., Pancetti S; Pathology Unit, Humanitas University, Pieve Emanuele, 20072 Milano, Italy.; Pathology Unit, Humanitas Research Hospital-IRCCS, Rozzano, 20089 Milano, Italy., Zuccalà V; Pathology Unit, Pugliese-Ciaccio Hospital Catanzaro, 88100 Catanzaro, Italy., Martino V; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy., Broggi G; Department of Medical and Surgical Sciences and Advanced Technologies 'G.F. Ingrassia' Anatomic Pathology, University of Catania, 95123 Catania, Italy., Caltabiano R; Department of Medical and Surgical Sciences and Advanced Technologies 'G.F. Ingrassia' Anatomic Pathology, University of Catania, 95123 Catania, Italy., Cavazza A; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy., Parente P; Pathology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013 Foggia, Italy., Mecucci C; Hematology, Centro di Ricerca Emato-Oncologica-C.R.E.O., University of Perugia, 06129 Perugia, Italy., Martino G; Hematology, Centro di Ricerca Emato-Oncologica-C.R.E.O., University of Perugia, 06129 Perugia, Italy.; Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy., Ascani S; Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Mar 08; Vol. 15 (6). Date of Electronic Publication: 2023 Mar 08.
DOI: 10.3390/cancers15061664
Abstrakt: Mast cell leukemia (MCL) is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate. MCL may develop de novo, in the absence of a prior SM, or it may represent a progression from a previous SM. MCL may be sub-divided into the more frequent, aggressive acute form with signs of organ damage (C-findings) and the chronic form lacking C-findings and presenting a more stable course, although over time, progression to acute MCL is common. The 2022 WHO subtype of MCL with an associated hematological neoplasm was renamed MCL with an associated myeloid neoplasm in the 2022 International Consensus Classification (ICC). The relevance of the distinction between the leukemic and aleukemic forms based on the percentage of circulating mast cells is a matter of debate. The current knowledge on MCL is restricted mainly to single reports or case series with a limited number of larger studies. Our aim is to provide a comprehensive overview of this rare disease in terms of clinical manifestations, morphology, phenotype, molecular characteristics, differential diagnosis, outcome and treatment. A general overview on mastocytosis is also included.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje